Lasting first impression: Pre-existing immunity restricts mucosal antibody responses during Omicron breakthrough
Summary Understanding mucosal antibody responses from SARS-CoV-2 infection and/or vaccination is crucial to develop strategies for longer term immunity, especially against emerging viral variants. We profiled serial paired mucosal and plasma antibodies from: COVID-19 vaccinated only vaccinees (vaccinated, uninfected), COVID-19 recovered vaccinees (convalescent, vaccinated) and individuals with breakthrough Delta or Omicron BA.2 infections (vaccinated, infected). Saliva from COVID-19 recovered vaccinees displayed improved antibody neutralizing activity, FcγR engagement and IgA compared to COVID-19 uninfected vaccinees. Furthermore, repeated mRNA vaccination boosted SARS-CoV-2-specific IgG2 and IgG4 responses in both mucosa biofluids (saliva and tears) and plasma. IgG, but not IgA, responses to breakthrough COVID-19 variants were dampened and narrowed by increased pre-existing vaccine-induced immunity to the ancestral strain. Salivary antibodies delayed initiation of boosting following breakthrough COVID-19 infection, especially Omicron BA.2, however, rose rapidly thereafter. Our data highlight how pre-existing immunity shapes mucosal SARS-CoV-2-specific antibody responses and has implications for long-term protection from COVID-19..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 09. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Selva, Kevin John [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.03.28.23287848 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI039122891 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI039122891 | ||
| 003 | DE-627 | ||
| 005 | 20231210091200.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230401s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.03.28.23287848 |2 doi | |
| 035 | |a (DE-627)XBI039122891 | ||
| 035 | |a (biorXiv)10.1101/2023.03.28.23287848 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Selva, Kevin John |e verfasserin |0 (orcid)0000-0002-0780-9422 |4 aut | |
| 245 | 1 | 0 | |a Lasting first impression: Pre-existing immunity restricts mucosal antibody responses during Omicron breakthrough |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary Understanding mucosal antibody responses from SARS-CoV-2 infection and/or vaccination is crucial to develop strategies for longer term immunity, especially against emerging viral variants. We profiled serial paired mucosal and plasma antibodies from: COVID-19 vaccinated only vaccinees (vaccinated, uninfected), COVID-19 recovered vaccinees (convalescent, vaccinated) and individuals with breakthrough Delta or Omicron BA.2 infections (vaccinated, infected). Saliva from COVID-19 recovered vaccinees displayed improved antibody neutralizing activity, FcγR engagement and IgA compared to COVID-19 uninfected vaccinees. Furthermore, repeated mRNA vaccination boosted SARS-CoV-2-specific IgG2 and IgG4 responses in both mucosa biofluids (saliva and tears) and plasma. IgG, but not IgA, responses to breakthrough COVID-19 variants were dampened and narrowed by increased pre-existing vaccine-induced immunity to the ancestral strain. Salivary antibodies delayed initiation of boosting following breakthrough COVID-19 infection, especially Omicron BA.2, however, rose rapidly thereafter. Our data highlight how pre-existing immunity shapes mucosal SARS-CoV-2-specific antibody responses and has implications for long-term protection from COVID-19. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Ramanathan, Pradhipa |0 (orcid)0000-0002-7390-8840 |4 aut | |
| 700 | 1 | |a Haycroft, Ebene Regina |0 (orcid)0000-0002-5059-3030 |4 aut | |
| 700 | 1 | |a Reynaldi, Arnold |0 (orcid)0000-0002-5529-5542 |4 aut | |
| 700 | 1 | |a Cromer, Deborah |0 (orcid)0000-0002-5276-5094 |4 aut | |
| 700 | 1 | |a Tan, Chee Wah |0 (orcid)0000-0001-9837-1413 |4 aut | |
| 700 | 1 | |a Wang, Lin-Fa |0 (orcid)0000-0003-2752-0535 |4 aut | |
| 700 | 1 | |a Wines, Bruce D |0 (orcid)0000-0002-4108-375X |4 aut | |
| 700 | 1 | |a Hogarth, P Mark |0 (orcid)0000-0002-0360-7890 |4 aut | |
| 700 | 1 | |a Downie, Laura E |0 (orcid)0000-0002-1596-2259 |4 aut | |
| 700 | 1 | |a Davis, Samantha K |0 (orcid)0000-0002-6197-4277 |4 aut | |
| 700 | 1 | |a Purcell, Ruth Amy |0 (orcid)0000-0001-6378-5114 |4 aut | |
| 700 | 1 | |a Kent, Helen E |4 aut | |
| 700 | 1 | |a Juno, Jennifer A |0 (orcid)0000-0002-9072-1017 |4 aut | |
| 700 | 1 | |a Wheatley, Adam K |0 (orcid)0000-0002-5593-9387 |4 aut | |
| 700 | 1 | |a Davenport, Miles P |0 (orcid)0000-0002-4751-1831 |4 aut | |
| 700 | 1 | |a Kent, Stephen John |0 (orcid)0000-0002-8539-4891 |4 aut | |
| 700 | 1 | |a Chung, Amy W |0 (orcid)0000-0003-0020-9704 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 09. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:09 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.03.28.23287848 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 09 |c 12 | ||